MRx0518 and Pembrolizumab Combination Study
Conditions: Oncology; Solid Tumor; Non Small Cell Lung Cancer; Renal Cell Carcinoma; Melanoma; Bladder Cancer Interventions: Drug: MRx0518; Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA] Sponsors: 4DPharma PLC; Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials